Cargando…

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction

Type 2 diabetes mellitus (T2DM) is associated with a high incidence of non-alcoholic fatty liver disease (NAFLD) related to obesity and insulin resistance. Currently, medical interventions for NAFLD have focused on diet control and exercise to reduce body weight, and there is a requirement for effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Komiya, Chikara, Tsuchiya, Kyoichiro, Shiba, Kumiko, Miyachi, Yasutaka, Furuke, Shunsaku, Shimazu, Noriko, Yamaguchi, Shinobu, Kanno, Kazuo, Ogawa, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792392/
https://www.ncbi.nlm.nih.gov/pubmed/26977813
http://dx.doi.org/10.1371/journal.pone.0151511
_version_ 1782421235197542400
author Komiya, Chikara
Tsuchiya, Kyoichiro
Shiba, Kumiko
Miyachi, Yasutaka
Furuke, Shunsaku
Shimazu, Noriko
Yamaguchi, Shinobu
Kanno, Kazuo
Ogawa, Yoshihiro
author_facet Komiya, Chikara
Tsuchiya, Kyoichiro
Shiba, Kumiko
Miyachi, Yasutaka
Furuke, Shunsaku
Shimazu, Noriko
Yamaguchi, Shinobu
Kanno, Kazuo
Ogawa, Yoshihiro
author_sort Komiya, Chikara
collection PubMed
description Type 2 diabetes mellitus (T2DM) is associated with a high incidence of non-alcoholic fatty liver disease (NAFLD) related to obesity and insulin resistance. Currently, medical interventions for NAFLD have focused on diet control and exercise to reduce body weight, and there is a requirement for effective pharmacological therapies. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are oral antidiabetic drugs that promote the urinary excretion of glucose by blocking its reabsorption in renal proximal tubules. SGLT2 inhibitors lower blood glucose independent of insulin action and are expected to reduce body weight because of urinary calorie loss. Here we show that an SGLT2 inhibitor ipragliflozin improves hepatic steatosis in high-fat diet-induced and leptin-deficient (ob/ob) obese mice irrespective of body weight reduction. In the obese mice, ipragliflozin-induced hyperphagia occurred to increase energy intake, attenuating body weight reduction with increased epididymal fat mass. There is an inverse correlation between weights of liver and epididymal fat in ipragliflozin-treated obese mice, suggesting that ipragliflozin treatment promotes normotopic fat accumulation in the epididymal fat and prevents ectopic fat accumulation in the liver. Despite increased adiposity, ipragliflozin ameliorates obesity-associated inflammation and insulin resistance in epididymal fat. Clinically, ipragliflozin improves liver dysfunction in patients with T2DM irrespective of body weight reduction. These findings provide new insight into the effects of SGLT2 inhibitors on energy homeostasis and fat accumulation and indicate their potential therapeutic efficacy in T2DM-associated hepatic steatosis.
format Online
Article
Text
id pubmed-4792392
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-47923922016-03-23 Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction Komiya, Chikara Tsuchiya, Kyoichiro Shiba, Kumiko Miyachi, Yasutaka Furuke, Shunsaku Shimazu, Noriko Yamaguchi, Shinobu Kanno, Kazuo Ogawa, Yoshihiro PLoS One Research Article Type 2 diabetes mellitus (T2DM) is associated with a high incidence of non-alcoholic fatty liver disease (NAFLD) related to obesity and insulin resistance. Currently, medical interventions for NAFLD have focused on diet control and exercise to reduce body weight, and there is a requirement for effective pharmacological therapies. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are oral antidiabetic drugs that promote the urinary excretion of glucose by blocking its reabsorption in renal proximal tubules. SGLT2 inhibitors lower blood glucose independent of insulin action and are expected to reduce body weight because of urinary calorie loss. Here we show that an SGLT2 inhibitor ipragliflozin improves hepatic steatosis in high-fat diet-induced and leptin-deficient (ob/ob) obese mice irrespective of body weight reduction. In the obese mice, ipragliflozin-induced hyperphagia occurred to increase energy intake, attenuating body weight reduction with increased epididymal fat mass. There is an inverse correlation between weights of liver and epididymal fat in ipragliflozin-treated obese mice, suggesting that ipragliflozin treatment promotes normotopic fat accumulation in the epididymal fat and prevents ectopic fat accumulation in the liver. Despite increased adiposity, ipragliflozin ameliorates obesity-associated inflammation and insulin resistance in epididymal fat. Clinically, ipragliflozin improves liver dysfunction in patients with T2DM irrespective of body weight reduction. These findings provide new insight into the effects of SGLT2 inhibitors on energy homeostasis and fat accumulation and indicate their potential therapeutic efficacy in T2DM-associated hepatic steatosis. Public Library of Science 2016-03-15 /pmc/articles/PMC4792392/ /pubmed/26977813 http://dx.doi.org/10.1371/journal.pone.0151511 Text en © 2016 Komiya et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Komiya, Chikara
Tsuchiya, Kyoichiro
Shiba, Kumiko
Miyachi, Yasutaka
Furuke, Shunsaku
Shimazu, Noriko
Yamaguchi, Shinobu
Kanno, Kazuo
Ogawa, Yoshihiro
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
title Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
title_full Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
title_fullStr Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
title_full_unstemmed Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
title_short Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
title_sort ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792392/
https://www.ncbi.nlm.nih.gov/pubmed/26977813
http://dx.doi.org/10.1371/journal.pone.0151511
work_keys_str_mv AT komiyachikara ipragliflozinimproveshepaticsteatosisinobesemiceandliverdysfunctionintype2diabeticpatientsirrespectiveofbodyweightreduction
AT tsuchiyakyoichiro ipragliflozinimproveshepaticsteatosisinobesemiceandliverdysfunctionintype2diabeticpatientsirrespectiveofbodyweightreduction
AT shibakumiko ipragliflozinimproveshepaticsteatosisinobesemiceandliverdysfunctionintype2diabeticpatientsirrespectiveofbodyweightreduction
AT miyachiyasutaka ipragliflozinimproveshepaticsteatosisinobesemiceandliverdysfunctionintype2diabeticpatientsirrespectiveofbodyweightreduction
AT furukeshunsaku ipragliflozinimproveshepaticsteatosisinobesemiceandliverdysfunctionintype2diabeticpatientsirrespectiveofbodyweightreduction
AT shimazunoriko ipragliflozinimproveshepaticsteatosisinobesemiceandliverdysfunctionintype2diabeticpatientsirrespectiveofbodyweightreduction
AT yamaguchishinobu ipragliflozinimproveshepaticsteatosisinobesemiceandliverdysfunctionintype2diabeticpatientsirrespectiveofbodyweightreduction
AT kannokazuo ipragliflozinimproveshepaticsteatosisinobesemiceandliverdysfunctionintype2diabeticpatientsirrespectiveofbodyweightreduction
AT ogawayoshihiro ipragliflozinimproveshepaticsteatosisinobesemiceandliverdysfunctionintype2diabeticpatientsirrespectiveofbodyweightreduction